Junichi Ikeda

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
To investigate the efficacy and safety of FOLFIRI plus bevacizumab regimen with irinotecan (180 mg/m2) in patients with advanced or recurrent colorectal cancer who were of the wild-type or heterozygous group for UGT1A1*28 and *6 polymorphisms and discontinued to oxaliplatin-based regimen, prospectively. The study population consisted of patients who had(More)
  • 1